Search
Dutasteride Drug Information Provided by Lexi-Comp

This information has been developed and provided by an independent third-party source. Merck & Co., Inc. does not endorse and is not responsible for the accuracy of the content, or for practices or standards of non-Merck sources.

Special Alerts

Five Alpha-Reductase Inhibitors (5-ARI): Increased Incidence of High-Grade Prostate Cancers

June 2011

The U.S. Food and Drug Administration (FDA) has notified healthcare providers about new safety information regarding the increased risk of being diagnosed with a more aggressive prostate cancer in patients taking 5-ARIs (eg, dutasteride, finasteride, and combinations containing a 5-ARI). Two large trials (Kaplan, 2009; Andriole, 2010) evaluated finasteride and dutasteride, respectively, in prostate cancer prevention. Results of both trials suggested that although the overall risk of being diagnosed with prostate cancer was low, the risk of a more aggressive prostate cancer diagnosis (Gleason Score [GS] 8-10) was increased. In the finasteride trial the incidence of GS 8-10 prostate cancer was 1.8% in the active treatment group versus 1.1% in the placebo group. Similarly in the dutasteride trial the risk of GS 8-10 prostate cancer diagnosis was higher in the active treatment group compared to placebo (0.9 % vs 0.6%). Although neither study demonstrated a statistical increase in risk, there was a trend that requires further evaluation.

The FDA is making the following suggestions for clinicians:

- Prior to initiating therapy with a 5-ARI, evaluate and rule out other urological etiologies including prostate cancer.

- 5-ARIs may reduce prostate-specific antigen (PSA) values by 50% within 6 months of initiation, although individual patients may experience varying decreases.

- Any confirmed increase in PSA in a patient maintained on a 5-ARI may be suggestive of prostate cancer and should be evaluated even if the PSA is within the normal range.

- 5-ARIs are not FDA-approved for prevention of prostate cancer .

For additional information, refer to http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm258529.htm.

Pronunciation

(doo TAS teer ide)

Generic Available (U.S.)

No

Brand Names: U.S.

  • Avodart®

Brand Names: Canada

  • Avodart®

Pharmacologic Category

  • 5 Alpha-Reductase Inhibitor

Use: Labeled Indications

Treatment of symptomatic benign prostatic hyperplasia (BPH) as monotherapy or combination therapy with tamsulosin

Use: Unlabeled

Treatment of male pattern baldness

Pregnancy Risk Factor

X

Pregnancy Considerations

Preclinical data (animal studies) suggests that the suppression of circulating levels of dihydrotestosterone may inhibit the development of the external genital organs and lead to feminization of a male fetus carried by a woman exposed to dutasteride. Pregnant woman and those who may become pregnant should not handle the capsules because dutasteride is absorbed through the skin. It is distributed into the semen.

Lactation

Excretion in breast milk unknown/contraindicated in women of childbearing potential

Contraindications

Hypersensitivity to dutasteride, other 5α-reductase inhibitors (eg, finasteride), or any component of the formulation; children; women of childbearing potential; pregnancy

Warnings/Precautions

Special handling:

• Hazardous agent: Use appropriate precautions for handling and disposal.

• Women/pregnancy: Active ingredient can be absorbed through the skin; women should always use caution whenever handling. Pregnant women or women trying to conceive should not handle the product; if contact with a leaking capsule occurs, wash area immediately with soap and water; dutasteride may negatively impact fetal development.

Disease-related concerns:

• Diminished urinary flow: Carefully monitor patients with a large residual urinary volume or severely diminished urinary flow for obstructive uropathy; these patients may not be candidates for dutasteride therapy.

• Hepatic impairment: Use with caution in patients with hepatic impairment.

• Prostate cancer: When compared to placebo, 5-alpha-reductase inhibitors (5-ARIs) have been shown to reduce the overall incidence of prostate cancer, although an increase in the incidence of high-grade prostate cancers has been observed; 5-ARIs are not approved in the U.S. or Canada for the prevention of prostate cancer.

Concurrent drug therapy issues:

• CYP3A4 inhibitors: Use with caution with concurrent use of potent, chronic CYP3A4 inhibitors.

Other warnings/precautions:

• Appropriate use: Other urological diseases, including prostate cancer, should be ruled out before initiating therapy.

• Blood donation: Avoid donating blood during or for 6 months following treatment cessation due to risk of administration to a pregnant female transfusion recipient.

• PSA monitoring: Reduces prostate specific antigen (PSA) by ~50% within 3-6 months of use. If following serial PSAs, re-establish a new baseline ≥3 months after treatment initiation; monitor PSA periodically thereafter. If interpreting an isolated PSA value in a patient treated for ≥3 months, then double the PSA value for comparison to a normal PSA value in an untreated man. Failure to demonstrate a meaningful PSA decrease (<50%) or a PSA increase while on this medication may be associated with an increased risk for prostate cancer (NCCN Prostate Cancer Early Detection Guidelines, v.1.2011). Patients on a 5-ARI with any increase in PSA levels, even if within normal limits, should be evaluated; may indicate presence of prostate cancer.

Adverse Reactions

1% to 10%: Endocrine & metabolic: Impotence (1% to 5%), libido decreased (≤3%), ejaculation disorders (≤1%), gynecomastia (including breast tenderness, breast enlargement; ≤1%)

<1%, postmarketing, and/or case reports: Angioedema, dizziness, cardiac failure, edema (localized), hypersensitivity, prostate cancer (high-grade), pruritus, rash, skin reactions (serious), TSH increased, urticaria

Note: Frequency of adverse events (except gynecomastia) tends to decrease with continued use (>6 months).

Metabolism/Transport Effects

Substrate of CYP3A4 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

CYP3A4 Inhibitors (Strong): May increase the serum concentration of Dutasteride. Risk C: Monitor therapy

Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates. Risk C: Monitor therapy

Ethanol/Nutrition/Herb Interactions

Ethanol: No effect or interaction noted.

Food: Maximum serum concentrations reduced by 10% to 15% when taken with food; not clinically significant.

Herb/Nutraceutical: St John's wort may decrease dutasteride levels. Avoid saw palmetto (concurrent use has not been adequately studied).

Storage

Store at controlled room temperature of 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Mechanism of Action

Dutasteride is a 4-azo analog of testosterone and is a competitive, selective inhibitor of both reproductive tissues (type 2) and skin and hepatic (type 1) 5α-reductase. This results in inhibition of the conversion of testosterone to dihydrotestosterone and markedly suppresses serum dihydrotestosterone levels.

Pharmacodynamics/Kinetics

Absorption: Absorbed via skin when handling capsules

Distribution: Vd: 300-500 L, ~12% of serum concentrations partitioned into semen

Protein binding: 99% to albumin; ~97% to α1-acid glycoprotein; >96% to semen protein

Metabolism: Hepatic via CYP3A4 isoenzyme; forms metabolites: 6-hydroxydutasteride has activity similar to parent compound, 4′-hydroxydutasteride and 1,2-dihydrodutasteride are much less potent than parent in vitro

Bioavailability: ~60% (range: 40% to 94%)

Half-life elimination: Terminal: ~5 weeks

Time to peak: 2-3 hours

Excretion: Feces (40% as metabolites, ~5% as unchanged drug); urine (<1% as unchanged drug); ~55% of dose unaccounted for

Dosage

Oral: Adults: Males: BPH: 0.5 mg once daily alone or in combination with tamsulosin

Dosage adjustment in renal impairment: No adjustment required

Dosage adjustment in hepatic impairment: Use caution; no specific adjustments recommended

Administration: Oral

May be administered without regard to meals. Capsule should be swallowed whole; do not chew or open; contact with opened capsule can cause oropharyngeal irritation. Should not be touched or handled by women who are pregnant or are of childbearing age.

Monitoring Parameters

Objective and subjective signs of relief of benign prostatic hyperplasia, including improvement in urinary flow, reduction in symptoms of urgency, and relief of difficulty in micturition; for serial PSA monitoring, establish a new baseline PSA level after 3 months of therapy and monitor PSA periodically thereafter.

Test Interactions

PSA levels decrease in treated patients. After 3 months of therapy, PSA levels stabilize to a new baseline that is ~50% of pretreatment values. If following serial PSAs in a patient, re-establish a new baseline after ≥3 months of use. If interpreting an isolated PSA value in a patient treated for ≥3 months, then double the PSA value for comparison.

Dietary Considerations

May be taken without regard to meals.

Geriatric Considerations

No dosage adjustment necessary.

Dental Health: Effects on Dental Treatment

No significant effects or complications reported

Dental Health: Vasoconstrictor/Local Anesthetic Precautions

No information available to require special precautions

Mental Health: Effects on Mental Status

None reported

Mental Health: Effects on Psychiatric Treatment

Nefazodone may increase dutasteride levels

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, softgel, oral:

Avodart®: 0.5 mg

Pricing: U.S. (www.drugstore.com)

Capsules (Avodart)

0.5 mg (30): $128.99

References

Andriole G, Bostwick D, Brawley O, et al, “Chemoprevention of Prostate Cancer in Men at High Risk: Rationale and Design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial,” J Urol, 2004, 172(4 Pt 1):1314-7.

Andriole G, Bostwick DG, Brawley OW, et al, “Effect of Dutasteride on the Risk of Prostate Cancer,” N Engl J Med, 2010, 362(13):1192-202.

Andriole G, Roehrborn C, Schulman C, et al, “Effect of Dutasteride on the Detection of Prostate Cancer in Men With Benign Prostatic Hyperplasia,” Urology, 2004, 64(3):537-41.

Kramer BS, Hagerty KL, Justman S, et al, “Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline,” J Clin Oncol, 2009, 27(9):1502-16.

National Comprehensive Cancer Network® (NCCN), “Clinical Practice Guidelines in Oncology™: Prostate Cancer Early Detection,” Version 1.2011. Available at http://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf

International Brand Names

  • Avidart (ES)
  • Avodart (AR, AT, AU, BB, BE, BG, BM, BS, BZ, CH, CN, CO, CR, CZ, DE, DK, DO, EC, EE, FI, FR, GB, GR, GT, GY, HK, HN, ID, IE, IL, IT, JM, KP, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PR, PT, RU, SE, SG, SR, SV, TH, TR, TT, TW)
  • Duprost (IN)

Lexi-Comp.com

Last full review/revision March 2012

Content last modified March 2012

Back to Top
Audio
Figures
Photographs
Tables
Videos

Copyright     © 2010-2011 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A.    Privacy    Terms of Use